List of works - Rachel N. Grisham

#523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer

scientific article published on 01 July 2018

A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer

scientific article published on 17 January 2020

A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)

A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers

scientific article published on 30 October 2020

A preoperative tool for estimating the risk of blood transfusion over an ovarian cancer debulking surgery (113)

scientific article published in August 2022

Abagovomab: An Anti-Idiotypic CA-125 Targeted Immunotherapeutic Agent for Ovarian Cancer ⬇️

scientific article published on February 1, 2011

Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models

scientific article published on 11 December 2019

Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum

scientific article published on 13 August 2022

BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer ⬇️

scientific article published on August 28, 2012

BRAFV600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary

scientific article published on 22 June 2018

BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer

scientific article published on 16 June 2020

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer

scientific article

Beyond the estrogen receptor: In search of predictive biomarkers for low‐grade serous ovarian cancer

scientific article published on 3 March 2023

Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation

scientific article published on 6 September 2017

CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.

scientific article published on 28 February 2018

Chemotherapy response in low‐grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies

scientific article published on 23 March 2023

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer

scientific article published on 01 August 2018

Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy

scientific article published on 12 July 2017

Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management

scientific article published on 5 January 2018

Competitive translation efficiency at the picornavirus type 1 internal ribosome entry site facilitated by viral cis and trans factors

scientific article published on April 2006

Corrigendum to "Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation" [Gynecol. Oncol. Rep. 22 (2017) 9-12].

scientific article published on 29 September 2017

ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

scientific article published in June 2022

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade

scientific article published on 22 November 2018

Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial

scientific article published in November 2024

Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study

scientific article published on 29 December 2020

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer

scientific article

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

scientific article published in June 2023

Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience

scientific article

Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer

scientific article published in September 2023

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline

scientific article published on 27 January 2020

Germline drivers of gynecologic carcinosarcoma (2274)

scientific article published in September 2023

Germline drivers of gynecologic carcinosarcomas

scientific article published in July 2023

Germline variants in non-BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival.

scientific article published in June 2023

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer

scientific article published on 2 December 2011

InSight Care Pilot Program: Redefining Seeing a Patient

scientific article published on 29 May 2020

Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma

scientific article published on 17 November 2020

Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level – A Memorial Sloan Kettering Cancer Center study

scientific article published in March 2023

Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study

scientific article published in September 2023

Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)

scientific article published in September 2023

Low-Grade Serous Carcinoma of the Ovary

scientific article published on July 2016

Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions

scientific article published on 18 September 2018

Low-Grade Serous Ovarian Cancer: Expert Consensus Report on the State of the Science

Low-grade serous ovarian cancer: State of the science

scientific article published on 20 January 2020

Low-grade serous ovarian cancer: expert consensus report on the state of the science

scientific article published on 17 August 2023

MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma

scientific article published on 20 April 2022

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

scientific article published on 21 August 2020

Management of advanced uterine leiomyosarcoma

scientific article published on July 2014

Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation

scientific article published on 11 November 2022

Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes

Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes (1242)

scientific article published in September 2023

Mitogen-Activated Protein Kinase Driven Rare Gynecologic Cancers and Evolving Therapeutic Targets

scholarly article published in May 2023

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

scientific article published on 15 August 2023

Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial

scientific article published in April 2023

Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma

scientific article published on 08 May 2012

Ovarian cancer mutational processes drive site-specific immune evasion

scientific article published on 14 December 2022

Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.

scientific article published in 2022

PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy

Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival

scientific article published in January 2024

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway

scientific article published on 27 December 2019

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

scientific article

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

scientific article

Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome

scientific article published on 26 December 2012

Postoperative morbidity after secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer: An exploratory analysis of a randomized phase II study evaluating hyperthermic intraperitoneal chemotherapy (530)

scientific article published in August 2022

Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study

scientific article published on 26 October 2020

Predicting outcomes in female germ cell patients using a modified International Germ Cell Cancer Collaborative Group classification system to guide management (100)

scientific article published in August 2022

Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management

scientific article published in March 2023

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

scientific article published on 20 October 2023

Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum

scientific article published on 02 November 2020

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience

Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes

scientific article published on 28 September 2021

Safety and feasibility of therapeutic anticoagulation for newly diagnosed venous thromboembolism in women who undergo neoadjuvant chemotherapy for advanced ovarian cancer

scientific article published on 7 December 2023

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

scientific article published on 01 June 2020

Somatic BAP1 Loss in Ovarian Serous Borderline Tumor and Recurrent Low-grade Serous Carcinoma From a Germline BAP1 Mutation Carrier

scientific article published on 11 January 2023

Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study

scientific article published on 16 November 2020

Targeted therapies for treatment of recurrent ovarian cancer

scientific article

Targeting Progesterone in Hormonally Responsive Ovarian Cancer ⬇️

scholarly article

Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors

scientific article published in February 2023

The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer

scientific article published on 01 January 2019

The highs and lows of serous ovarian cancer

scientific article published on 27 June 2023

The roles of pathology in targeted therapy of women with gynecologic cancers

scientific article published on 23 November 2017

Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers

scientific article published on 19 August 2011

Transforming ovarian cancer care by targeting minimal residual disease

scientific article published in November 2023

Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer

scientific article published on 8 November 2016

List of works by Rachel N. Grisham

#523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer

A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer

A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)

A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers

A preoperative tool for estimating the risk of blood transfusion over an ovarian cancer debulking surgery (113)

Abagovomab: An Anti-Idiotypic CA-125 Targeted Immunotherapeutic Agent for Ovarian Cancer ⬇️

Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models

Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum

BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer ⬇️

BRAFV600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary

BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer

Beyond the estrogen receptor: In search of predictive biomarkers for low‐grade serous ovarian cancer

Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation

CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.

Chemotherapy response in low‐grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer

Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy

Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management

Competitive translation efficiency at the picornavirus type 1 internal ribosome entry site facilitated by viral cis and trans factors

Corrigendum to "Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation" [Gynecol. Oncol. Rep. 22 (2017) 9-12].

ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade

Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial

Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience

Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline

Germline drivers of gynecologic carcinosarcoma (2274)

Germline drivers of gynecologic carcinosarcomas

Germline variants in non-BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival.

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer

InSight Care Pilot Program: Redefining Seeing a Patient

Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma

Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level – A Memorial Sloan Kettering Cancer Center study

Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study

Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)

Low-Grade Serous Carcinoma of the Ovary

Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions

Low-Grade Serous Ovarian Cancer: Expert Consensus Report on the State of the Science

Low-grade serous ovarian cancer: State of the science

Low-grade serous ovarian cancer: expert consensus report on the state of the science

MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Management of advanced uterine leiomyosarcoma

Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation

Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes

Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes (1242)

Mitogen-Activated Protein Kinase Driven Rare Gynecologic Cancers and Evolving Therapeutic Targets

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial

Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma

Ovarian cancer mutational processes drive site-specific immune evasion

Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.

PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy

Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome

Postoperative morbidity after secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer: An exploratory analysis of a randomized phase II study evaluating hyperthermic intraperitoneal chemotherapy (530)

Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study

Predicting outcomes in female germ cell patients using a modified International Germ Cell Cancer Collaborative Group classification system to guide management (100)

Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience

Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes

Safety and feasibility of therapeutic anticoagulation for newly diagnosed venous thromboembolism in women who undergo neoadjuvant chemotherapy for advanced ovarian cancer

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

Somatic BAP1 Loss in Ovarian Serous Borderline Tumor and Recurrent Low-grade Serous Carcinoma From a Germline BAP1 Mutation Carrier

Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study

Targeted therapies for treatment of recurrent ovarian cancer

Targeting Progesterone in Hormonally Responsive Ovarian Cancer ⬇️

Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors

The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer